TScan Therapeutics, Inc.

TCRX · Nasdaq · SIC 2836: Biological Products, (No Diagnostic Substances)
98
SEC Filings

Business Summary

PART I Overview We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. Our lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The product is designed to eliminate residual di...

Next Earnings

Q2 FY2026 — expected 2026-09-10

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionTCRXdiscussed_in_filing Cybersecurity
topic_mentionTCRXdiscussed_in_filing Cybersecurity

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-042025-12-310001193125-26-089884EDGAR109K words
2025-03-052024-12-310000950170-25-033077EDGAR—
2024-03-062023-12-310000950170-24-026875EDGAR—
2023-03-082022-12-310000950170-23-006589EDGAR—
2022-03-092021-12-310000950170-22-003175EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-122025-09-300001193125-25-275933EDGAR71K words
2025-08-122025-06-300000950170-25-106919EDGAR—
2025-05-062025-03-310000950170-25-063968EDGAR—
2024-11-122024-09-300000950170-24-124575EDGAR—
2024-08-122024-06-300000950170-24-095066EDGAR—
2024-05-132024-03-310000950170-24-058198EDGAR—
2023-11-092023-09-300000950170-23-061533EDGAR—
2023-08-102023-06-300000950170-23-040961EDGAR—
2023-05-102023-03-310000950170-23-020087EDGAR—
2022-11-092022-09-300000950170-22-023507EDGAR—
2022-08-102022-06-300000950170-22-016263EDGAR—
2022-05-122022-03-310000950170-22-009472EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-04-020001193125-26-138973EDGAR1K words
2026-03-040001193125-26-089871EDGAR—
2026-01-120001193125-26-009771EDGAR—
2025-11-260001193125-25-300538EDGAR—
2025-11-120001193125-25-275889EDGAR—
2025-11-030001193125-25-261612EDGAR—
2025-09-090001193125-25-198768EDGAR—
2025-08-200001193125-25-184083EDGAR—
2025-08-120000950170-25-106915EDGAR—
2025-07-020001193125-25-154336EDGAR—

98 total filings indexed. 71 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

FDMT — 4D Molecular Therapeutics, Inc. APTN — ADAPTIN BIO, INC. ADMA — ADMA BIOLOGICS, INC. AGEN — AGENUS INC AIM — AIM ImmunoTech Inc. AMGN — AMGEN INC AVXL — ANAVEX LIFE SCIENCES CORP. ABPO — Abpro Holdings, Inc.

Company Identity

CIK0001783328
TickerTCRX
ExchangeNasdaq
SIC2836: Biological Products, (No Diagnostic Substances)
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 552784c5a0663927b412343c9801515a3a9cfbd08bf1a3d1c5044dc54e53c9ae
parent: ce33a503e2d3615d14537b7e9687f3d3a772ca260b8389815ecafd41708f0c6d
content hash: 19f2ded4fb372c99389990220ca9b9541fd3221fb32805111921358a0f28c3dc
signed: 2026-04-13T04:47:44.756Z
sources: 17 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf